Table 2.
Adverse effects of midostaurin (non-hematologic)
| Event | Any grade (occurring in 10% or more of patients) | Grade 3 or 4 |
|---|---|---|
| Nausea | 79% | 6% |
| Vomiting | 66% | 6% |
| Diarrhea | 54% | 8% |
| Peripheral edema | 34% | 4% |
| Abdominal pain | 28% | 3% |
| Fatigue | 28% | 9% |
| Pyrexia | 27% | 6% |
| Constipation | 24% | 1% |
| Headache | 23% | 2% |
| Back pain | 20% | 2% |
| Pruritus | 19% | 3% |
| Arthralgia | 17% | 2% |
| Cough | 16% | 1% |
| Dyspnea | 16% | 4% |
| Musculoskeletal pain | 16% | 4% |
| Nasopharyngitis | 15% | 0 |
| Urinary tract infection | 12% | 2% |
| Dizziness | 11% | 0 |
| Epistaxis | 11% | 3% |
| Pleural effusion | 11% | 3% |
| QTc-interval prolongation | 10% | 1% |
Abbreviation: MCs, mast cells.